American journal of respiratory cell and molecular biology · 2026
Metabolic alterations in cystic fibrosis lymphocyte memory accompany restoration of CFTR function.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saavedra Milene T, Rysavy Noel M, Poch Katie R, Caceres Silvia M, Leach Sonia M, Laborda Curtis, Leti Fatjon, Walton Kendra N, Danhorn Thomas, Reisz Julie A, D'Alessandro Angelo, Taylor-Cousar Jennifer L, Nick Jerry A, Reinhardt R Lee, Bratcher Preston E, Vestal Brian E
Аннотация
RATIONALE: Elexacaftor/tezacaftor/ivacaftor (ETI) broadly improves outcomes in cystic fibrosis (CF). Cystic fibrosis transmembrane conductance regulator (CFTR) correction by ETI is incomplete, and patients with established disease continue to experience infection. We hypothesized that CFTR restoration by ETI would modify T-cell memory, providing a basis for improved infectious outcomes after treatment.
OBJECTIVES: To evaluate ETI modification of lymphocyte signatures using transcriptomics and metabolomics in blood samples taken from adults with CF (awCF).
METHODS AND MAIN RESULTS: Circulating CD3+ T cells from awCF (n = 18) before and after ETI initiation were evaluated by cellular indexing of transcriptomes and epitopes by sequencing. Single-cell data profiled multiple T-cell populations, including naive, memory, and effector states, with the most extensive changes occurring in CD4+ T-cell populations. Simultaneous plasma metabolomic measurements were analyzed in association with CD4+ T-cell metabolic gene signatures. The relationships between clinical outcomes, cell-specific gene expression, and metabolomics were evaluated using generalized linear mixed models. The effect of reduced CFTR in lymphocytes was evaluated in vitro using CRISPR/Cas9-mediated CFTR knockdown in primary human lymphocyte cultures, as well as in splenocytes harvested from CFTR knockout mice.
CONCLUSIONS: We reveal that altered metabolism occurs within the CD4+ T memory compartment following CFTR modulation, identifying multiple previously unrecognized changes in memory functions. Memory T-cell metabolic switches are highly related to a reduction in hospitalizations after treatment. Adaptive immune memory in awCF after modulator therapy is highly associated with improved outcomes from CF pulmonary infections, with variation seen in individuals experiencing lesser benefit after modulators.
OBJECTIVES: To evaluate ETI modification of lymphocyte signatures using transcriptomics and metabolomics in blood samples taken from adults with CF (awCF).
METHODS AND MAIN RESULTS: Circulating CD3+ T cells from awCF (n = 18) before and after ETI initiation were evaluated by cellular indexing of transcriptomes and epitopes by sequencing. Single-cell data profiled multiple T-cell populations, including naive, memory, and effector states, with the most extensive changes occurring in CD4+ T-cell populations. Simultaneous plasma metabolomic measurements were analyzed in association with CD4+ T-cell metabolic gene signatures. The relationships between clinical outcomes, cell-specific gene expression, and metabolomics were evaluated using generalized linear mixed models. The effect of reduced CFTR in lymphocytes was evaluated in vitro using CRISPR/Cas9-mediated CFTR knockdown in primary human lymphocyte cultures, as well as in splenocytes harvested from CFTR knockout mice.
CONCLUSIONS: We reveal that altered metabolism occurs within the CD4+ T memory compartment following CFTR modulation, identifying multiple previously unrecognized changes in memory functions. Memory T-cell metabolic switches are highly related to a reduction in hospitalizations after treatment. Adaptive immune memory in awCF after modulator therapy is highly associated with improved outcomes from CF pulmonary infections, with variation seen in individuals experiencing lesser benefit after modulators.